On the stock market since 2025, it operates in the world of health and science. It has 7 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 58% below its peak. The market has trimmed its expectations for the company.
The average analyst price target is $22.00 — 471% above today’s price.
A loss of $1.5M against $0 in annual sales.
This stock swings about 4 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, NSRX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NSRX is a high-risk stock — not yet profitable, and its future rides on its product catching on.